This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sovinz, P.
Right arrow Articles by Dornbusch, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sovinz, P.
Right arrow Articles by Dornbusch, H.
Related Collections
Right arrow Tumors

PEDIATRICS Vol. 107 No. 6 June 2001, p. e104

ELECTRONIC ARTICLE:
Tunneled Femoral Central Venous Catheters in Children With Cancer

Received Sep 1, 2000; accepted Jan 24, 2001.

Petra Sovinz, Christian Urban, Herwig Lackner, Reinhold Kerbl, Wolfgang Schwinger, and Hansjürgen Dornbusch

From the Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Graz, Auenbruggerplatz, Graz, Austria.

Objective.  We discuss the feasibility of long-term femoral venous access by means of a cuffed subcutaneously tunneled central venous catheter (Broviac catheter) in selected pediatric cancer and stem cell transplant patients in whom access via the veins of the upper part of the torso is difficult or contraindicated and in whom alternative routes must be used.

Patients and Methods.  We report on our experience with 9 patients (3 of whom underwent stem cell transplantation) who received femoral Broviac catheters between December 1990 and November 1999.

Results.  Time in place ranged from 4 to 155 days with a median of 58 days (mean: 71.2 days). Three catheters had to be removed: 1 because of infection of the subcutaneous tunnel and 2 because of catheter obstruction. The remaining 6 catheters functioned well without problems as long as they were needed; 1 of them got accidentally dislodged while the patient was off treatment. No episodes of catheter-related septicemia, thrombosis, kinking, or drug extravasation were noted; there were no catheter-related infectious complications in the transplant patients.

Conclusions.  Our experience indicates that in those instances in which customary access to the superior vena cava is precluded, long-term venous access by way of the femoral vein is a feasible and safe alternative in children, even in the setting of stem cell transplantation.  Key words:  femoral long-term central venous catheters, Broviac, pediatric cancer patients.